11,400 Shares in AtriCure, Inc. $ATRC Acquired by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund bought a new position in AtriCure, Inc. (NASDAQ:ATRC) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 11,400 shares of the medical device company’s stock, valued at approximately $641,000.

Other hedge funds also recently made changes to their positions in the company. ProShare Advisors LLC acquired a new stake in shares of AtriCure during the 3rd quarter valued at approximately $385,000. MGO One Seven LLC acquired a new position in AtriCure in the third quarter worth $318,000. Verdence Capital Advisors LLC acquired a new position in AtriCure in the third quarter worth $231,000. Sterling Capital Management LLC boosted its holdings in AtriCure by 841.1% in the third quarter. Sterling Capital Management LLC now owns 1,647 shares of the medical device company’s stock worth $93,000 after purchasing an additional 1,472 shares during the period. Finally, Yousif Capital Management LLC bought a new stake in AtriCure during the third quarter valued at $762,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. BTIG Research increased their target price on shares of AtriCure from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Canaccord Genuity Group raised their price target on shares of AtriCure from $55.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Citizens Jmp lifted their price target on shares of AtriCure from $52.00 to $68.00 and gave the company a “market outperform” rating in a report on Wednesday, October 21st. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Wednesday, October 21st. Finally, Needham & Company LLC boosted their price objective on shares of AtriCure from $64.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $61.80.

AtriCure Price Performance

Shares of NASDAQ:ATRC opened at $56.26 on Wednesday. The firm’s 50 day moving average is $57.15 and its two-hundred day moving average is $38.90. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $66.02. The firm has a market capitalization of $2.86 billion, a P/E ratio of 187.54 and a beta of 1.23. The company has a current ratio of 4.33, a quick ratio of 3.29 and a debt-to-equity ratio of 0.17.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.23. The company had revenue of $154.45 million for the quarter, compared to analysts’ expectations of $151.05 million. AtriCure had a return on equity of 4.01% and a net margin of 2.52%. Analysts anticipate that AtriCure, Inc. will post 0.44 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Karl Dahlquist sold 9,370 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $48.89, for a total value of $458,099.30. Following the sale, the insider directly owned 87,319 shares in the company, valued at $4,269,025.91. This trade represents a 9.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Regina Groves sold 5,313 shares of AtriCure stock in a transaction on Friday, September 11th. The shares were sold at an average price of $54.22, for a total value of $288,070.86. Following the sale, the director directly owned 34,546 shares in the company, valued at $1,873,084.12. The trade was a 13.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 39,026 shares of company stock valued at $2,172,263 in the last three months. 4.00% of the stock is currently owned by corporate insiders.

AtriCure Company Profile

AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.